Signal Genetics has entered into an agreement to purchase ChipDX's assets and patents for prognostic tests including BreastGeneDX, ColonGeneDX, and LungGeneDX.
Signal will also purchase ChipDX’s web-based interface, which will be used to enhance its physician web portal and allow for remote interpretation of test algorithms.
Signal said the acquired tests will leverage the technology platform currently used by them, thus their subsidiaries will also provide economies of scale to its currently marketed multiple myeloma prognostic test, MyPRS Plus.
As part of the acquisition, ChipDX’s CEO and founder Ryan VanLaar will join Signal as the head of BioInformatics.
Signal Genetics president and CEO Joe Hernandez said the addition of ChipDX’s bioinformatics capabilities reduces their time to commercialize with molecular tests designed to facilitate better patient outcomes at a lower cost profile.
ChipDX CEO and founder Ryan van Laar said joining forces with Signal provides them with a vehicle to commercialize their portfolio of predictive molecular diagnostic tests.
"I look forward to leverage the experience gained in the development of ChipDX to help Signal Genetics achieve its goals, and improve patient outcomes,"Laar said.